US20170348246A1 - Packaging body for patch and method of packing patch - Google Patents

Packaging body for patch and method of packing patch Download PDF

Info

Publication number
US20170348246A1
US20170348246A1 US15/538,179 US201515538179A US2017348246A1 US 20170348246 A1 US20170348246 A1 US 20170348246A1 US 201515538179 A US201515538179 A US 201515538179A US 2017348246 A1 US2017348246 A1 US 2017348246A1
Authority
US
United States
Prior art keywords
patch
drug
layer
sensitive adhesive
pressure sensitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/538,179
Other languages
English (en)
Inventor
Yukiko Tohara
Kyohei Matsuo
Ayaka Ohba
Sayaka Naruse
Kanako INAGAKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nichiban Co Ltd
Original Assignee
Nichiban Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nichiban Co Ltd filed Critical Nichiban Co Ltd
Assigned to NICHIBAN CO., LTD. reassignment NICHIBAN CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MATSUO, Kyohei, INAGAKI, Kanako, NARUSE, Sayaka, OHBA, Ayaka, TOHARA, Yukiko
Publication of US20170348246A1 publication Critical patent/US20170348246A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes

Definitions

  • Patent Literature 1 proposes a packaging bag for patch in which a hygroscopic member layer, a water permeable member layer, and a shielding member layer are laminated for the purpose of providing a packaging bag for patch which can sufficiently decrease the influence of moisture on the drug in a patch so as to stably store the patch for a long period of time and also exhibits excellent economic efficiency and handling property.
  • Patent Literature 2 proposes a packaging structure obtained by hermetically packing the entire patch in which a pressure sensitive adhesive layer containing a fatty acid ester and/or a glycerin ester as an organic liquid component having a melting point of 25° C. or lower at from 40 weight % to 70 weight % in a compatible state is provided on one surface of a support, in which the packaging material is a laminate and the inner surface thereof is formed of an ethylene/vinyl alcohol copolymer film or an acrylonitrile/methyl acrylate copolymer film as a plastic material having a solubility parameter of 9 or more.
  • Patent Literature 3 proposes a laminated packaging bag housing a transdermal absorbent that permeates a medicinal ingredient via the skin, in which at least one layer of the heat-sealed layer includes an ethylene-vinyl alcohol copolymer (EVOH) layer and has a chuck-like opening composed of polyethylene.
  • EVOH ethylene-vinyl alcohol copolymer
  • Patent Literature 5 describes an example in which an oxidation inhibitor (BHT) is blended in a transdermal absorption type preparation in order to improve storage stability thereof.
  • BHT oxidation inhibitor
  • Patent Literature 6 describes that an acrylic pressure sensitive adhesive exhibits high polymerizability, a high cohesive force, and sufficient adhesive property and can stably retain a large amount of local anesthetic.
  • Patent Literature 7 describes that a stable base layer can be formed by blending a vinyl acetate resin.
  • rivastigmine is one of acetylcholinesterase inhibitors and used as a therapeutic agent for Alzheimer type dementia (antidementia drug), and in recent years, the transdermal administration thereof, namely, administration thereof using a patch has also been proposed.
  • Patent Literature 8 Patent Literature 9
  • Patent Literature 5 a preparation in which a silicone pressure sensitive adhesive is pasted to a storage layer containing rivastigmine has been reported, but the silicone pressure sensitive adhesive has a problem that the cost of the pressure sensitive adhesive itself is high and the cost of the release liner is also high since it is required to be subjected to special processing.
  • a patch (Patent Literature 11) using an acryl-rubber hybrid adhesive having a hydroxyl group is proposed from the viewpoint of improving the skin permeability of rivastigmine and decreasing the skin irritation by the pressure sensitive adhesive layer
  • a patch (Patent Literature 12) in which a nonvolatile substance such as citric acid is contained in an acrylic pressure sensitive adhesive layer having a hydroxyl group and the like has been proposed for the purpose of decreasing the loss of the active substance (drug) due to the volatilization in the manufacturing process.
  • the stability of rivastigmine is not discussed in these literatures.
  • the present inventors have conducted intensive studies to solve the above problems, and they have investigated the configurations of packaging materials to house these patches in order to eliminate temporal instability of a drug of which the stability is susceptible to oxidation, volatilization, and adsorption, particularly a patch containing lidocaine of a local anesthetic and rivastigmine of an antidementia drug.
  • the present invention provides the following patch product as an aspect.
  • a patch product comprising:
  • the laminate has a laminate configuration having a heat sealable cyclic polyolefin film as an innermost layer of the packaging bag, an oxygen blocking layer as a layer on an outer side of the cyclic polyolefin film, and an outer layer as a layer on an outer side of the oxygen blocking layer disposed, respectively.
  • the present invention provides the following patch product.
  • the patch includes:
  • a support which contains a drug and is provided on at least one surface of the support, and a pressure sensitive adhesive layer provided on the drug-containing layer, or
  • a support a pressure sensitive adhesive layer provided on at least one surface of the support, and a drug-containing layer which contains a drug and is provided on the pressure sensitive adhesive layer, or
  • a support and a drug-containing pressure sensitive adhesive layer provided on at least one surface of the support.
  • the support is a fabric selected from the group consisting of a nonwoven fabric, a woven fabric, and a knitted fabric.
  • the support includes at least one kind of material selected from the group consisting of polyester and polyolefin.
  • the present invention provides a method of manufacturing the patch product described above as an aspect.
  • the present invention relates to a patch product equipped with a packaging bag and a patch which contains a drug and is housed in the packaging bag, particularly a patch containing a drug (lidocaine or rivastigmine) of which the stability is susceptible to oxidation, volatilization, and adsorption.
  • a drug lidocaine or rivastigmine
  • the drug contained in a patch to be a target of the patch product of the present invention for example, lidocaine is considered to be easily adsorbed and rivastigmine is considered to be relatively susceptible to oxidation and volatilization.
  • the patches containing these drugs are housed in a packaging bag fabricated with a highly non-adsorptive, sealable, and light blocking packaging material and stored until immediately before being used.
  • the packaging bag to be used in the present invention is formed of a laminate composed of at least three or more layers including a cyclic polyolefin film (hereinafter, also referred to as the COC film).
  • a cyclic polyolefin film hereinafter, also referred to as the COC film.
  • the laminate has a laminate configuration in which a heat sealable cyclic polyolefin film as an innermost layer of the packaging bag, an oxygen blocking as a layer on the outer side of the cyclic polyolefin film, and an outer layer as a layer on the outer side of the oxygen blocking layer are disposed, respectively.
  • the cyclic polyolefin film can be formed of a cyclic olefin polymer (also referred to as COP) composed only of a cyclic olefin component, a cyclic olefin copolymer that is a copolymer of a cyclic olefin component with an olefin component such as ethylene, or a blended polymer obtained by blending a cyclic olefin polymer or a cyclic olefin copolymer with another polyolefin resin.
  • a cyclic olefin polymer also referred to as COP
  • Examples of the cyclic olefin component in the COC film may include cyclohexane or a derivative thereof, cycloheptene or a derivative thereof, cyclooctene or a derivative thereof, cyclononene or a derivative thereof, cyclodecene or a derivative thereof, bicyclo[2.2.1]hept-2-ene or a derivative thereof, tetracyclo[4.4.0.1 2,5 .1 7,10 ]-3-dodecene or a derivative thereof, hexacyclo[6.6.1.1 3,6 .1 10,13 .0 2,7 .0 9,14 ]-4-heptadecene or a derivative thereof, octacyclo[8.8.0.1 2,9 .1 4,7 .1 11,10 .1 13,16 .0 3,8 .0 12,17 ]-5-docosene or a derivative thereof, pentacyclo[6.6.1.1 3,6 .0 2,7 .0 9,
  • examples of the cyclic olefin component may include ring-opened products and hydrogenated products thereof such as bicyclo[2.2.1]hept-2-ene or a derivative thereof, tetracyclo[4.4.0.1 2,5 .1 7,10 ]-3-dodecene or a derivative thereof, hexacyclo[6.6.1.1 3,6 .1 10,13 .0 2,7 .0 9,14 ]-4-heptadecene or a derivative thereof, octacyclo[8.8.0.1 2,9 .1 4,7 .1 11,10 .1 13,16 .0 3,8 .0 12,17 ]-5-docosene or a derivative thereof, pentacyclo[6.6.1.1 3,6 .0 2,7 .0 9,14 ]-4-hexadecene or a derivative thereof, pentacyclo[6.5.1.1 3,6 .0 2,7 .0 9,13 ]-4-pentadecene or a derivative thereof,
  • the structural unit derived from the olefin component such as ethylene is suitably in a range of from 40 mol % to 95 mol % and the structural unit derived from the cyclic olefin component is usually suitably in a range of from 5 mol % to 60 mol %.
  • COC polymer for example, TOPAS (registered trademark, manufactured by Polyplastics Co., Ltd.), APEL (registered trademark, manufactured by Mitsui Chemicals, Inc.), and ARTON (registered trademark, manufactured by JSR Corporation) of a commercially available product can be used.
  • TOPAS registered trademark, manufactured by Polyplastics Co., Ltd.
  • APEL registered trademark, manufactured by Mitsui Chemicals, Inc.
  • ARTON registered trademark, manufactured by JSR Corporation
  • the COC film can be a film blended with an olefin resin such as a linear low density polyethylene (LLDPE) resin, a high density polyethylene (HDPE) resin, or a polypropylene (PP) resin in consideration of adhesive property (heat sealability), the amount of low molecular weight substance eluted, and the like.
  • the blending rate (mass ratio) of the resin other than COC constituting the COC film is preferably from 3 mass % to 50 mass % and particularly preferably from 5 mass % to 10 mass %.
  • the density of linear low density polyethylene is from 0.935 to 0.950
  • the density of high density polyethylene is from 0.940 to 0.975
  • polypropylene may be either a homo or block type, but a homo type is preferred.
  • the COC film may further contain one kind or two or more kinds of additives such as an oxidation inhibitor, an ultraviolet absorber, a light stabilizer, an antistatic agent, an antiblocking agent, a lubricant (fatty acid amide or the like), a flame retardant, an inorganic or organic filler, a crosslinking agent, a coloring agent such as a dye or a pigment, and a modifying resin if necessary.
  • additives such as an oxidation inhibitor, an ultraviolet absorber, a light stabilizer, an antistatic agent, an antiblocking agent, a lubricant (fatty acid amide or the like), a flame retardant, an inorganic or organic filler, a crosslinking agent, a coloring agent such as a dye or a pigment, and a modifying resin if necessary.
  • the blending rate of the olefin-based resin is more than 50 mass %, it is concerned that the non-adsorptive property of cyclic polyolefin is impaired and also the transparency deteriorates in some cases although the effect of the present invention is not directly affected.
  • the COC film has a minimum thickness capable of fabricating a hermetically sealed packaging bag by heat sealing, and the thickness is from 10 ⁇ m to 50 ⁇ m, and for example, preferably 30 ⁇ m.
  • COC film for example, ZeonorFilm (registered trademark, manufactured by ZEON CORPORATION) of a commercially available product can be used.
  • the oxygen blocking layer to be disposed on the outer side of the COC film may be any material as long as it can block the incorporation of oxygen from the outside of the packaging bag.
  • a vapor deposited layer formed by aluminum vapor deposition, silica vapor deposition, alumina vapor deposition, and silica alumina binary vapor deposition, and the like can be adopted in addition to a soft metal foil such as an aluminum foil.
  • a multilayered body for example, nylon 6/MXD/nylon 6, or nylon 6/cyclic polyolefin/nylon 6) or a mixture of the above resin films may be used.
  • the outer layer has a function to maintain the strength of the laminate itself, a function as a base material to support the oxygen blocking layer, and a function to counteract the external physical stimulus or chemical stimulus (pressure, friction, and the like) when it is formed into a packaging bag, and it may be in the form of one outer layer having all of these functions or in the form of a plurality of outer layers in which these functions are shared among the plurality of layers.
  • the “outer layer” means a layer positioned on the outer side of the oxygen blocking layer, and it may be a layer having the positional relationship.
  • the packaging bag to be used in the present invention is formed of a laminate composed of at least three or more layers including a cyclic polyolefin (COC) film.
  • the laminate may be one in which a heat sealable COC film as the innermost layer of the packaging bag, an oxygen blocking layer as a layer on the outer side of the COC film, and an outer layer as a layer on the outer side of the oxygen blocking layer are disposed.
  • the packaging bag may have an aspect in which a plurality of the COC film, the oxygen blocking layer, and the outer layer are disposed.
  • the laminate may have a laminate configuration which further includes layers other than the COC film, the oxygen blocking layer, and the outer layer if necessary.
  • the laminate can be manufactured by dry lamination, extrusion lamination, or coextrusion lamination, and the thickness of the laminate can be set to about 10 ⁇ m to 100 ⁇ m.
  • the respective layers are directly laminated or laminated via an adhesive or the like.
  • an adhesive to which the drug is hardly adsorbed.
  • an isocyanate such as TDI or MDI is used as the adhesive, or a polyurethane adhesive blended with a polyol or the like can be used.
  • the packaging body is formed to be one size larger than the lidocaine-containing patch or rivastigmine-containing patch.
  • the packaging body has a size to be from 1.5-fold to 10-fold the patch.
  • a patch including a support, a pressure sensitive adhesive layer provided on at least one surface of the support, and a drug-containing layer which contains a drug and is provided on the pressure sensitive adhesive layer.
  • a patch including a support and a drug-containing pressure sensitive adhesive layer provided on at least one surface of the support.
  • the patch to be a target of the present invention for example, it is possible to preferably use a fabric selected from the group consisting of a nonwoven fabric, a woven fabric, and a knitted fabric.
  • a flexible material so as to be able to come in close contact with the skin and follow the movement of the skin and a material which can suppress the occurrence of skin rash after being attached for a long period of time are preferable.
  • a knitted fabric and the like are preferable and a polyester knitted fabric is particularly preferable.
  • the polyolefin film and polyester film described above are also suitably used.
  • the drug (lidocaine or rivastigmine) contained in the drug-containing layer or the drug-containing pressure sensitive adhesive layer is not adsorbed to the support and the drug (lidocaine or rivastigmine) is not released from the support side.
  • the drug (lidocaine or rivastigmine) contained in the drug-containing layer or the drug-containing pressure sensitive adhesive layer is not adsorbed to the support and the drug (lidocaine or rivastigmine) is not released from the support side.
  • the moisture permeability to be measured at 40° C.
  • the support is preferably 300 g/m 2 ⁇ 24 hr or less and particularly preferably 50 g/m 2 ⁇ 24 hr or less.
  • the form of a plastic film exhibiting excellent transparency from the viewpoint of preventing the patch from being noticeable at the time of being attached, that is, the color tone of the skin while being attached is easily seen through.
  • a coloring agent may include a pigment, an organic pigment, and a natural colourant.
  • the thickness thereof is preferably from 50 ⁇ m to 1 mm, more preferably from 100 ⁇ m to 800 ⁇ m, and still more preferably from 200 ⁇ m to 700 ⁇ m, and the basis weight is preferably 300 g/m 2 or less, more preferably 200 g/m 2 or less, and still more preferably 150 g/m 2 or less from the viewpoint of followability to the skin.
  • the thickness thereof is preferably from 10 ⁇ m to 300 ⁇ m, more preferably from 12 ⁇ m to 200 ⁇ m, and still more preferably from 15 ⁇ m to 150 ⁇ m.
  • the thickness of the support is thinner than 5 ⁇ m, the strength and handling property of the patch deteriorate, thus the patch is hardly attached to the skin, is broken by contact with other members and the like, or peels off from the skin in a short time by contact with water at the time of bathing and the like in some cases.
  • the support is a film
  • one surface or both surfaces of the support may be subjected to a treatment such as a sandblasting treatment or a corona treatment for the purpose of improving the anchoring property of the pressure sensitive adhesive with the support.
  • the support may contain additives such as an antistatic agent and an ultraviolet inhibitor to an extent that the effect of the present invention is not impaired.
  • the antistatic agent may include surfactants (an anionic surfactant, a cationic surfactant, a nonionic surfactant, and an amphoteric surfactant). By antistatic agent, it is possible to eliminate the anchoring property of the support and process defects.
  • the drug to be applied to the patch to be a target of the present invention is not particularly limited.
  • a systemic drug may include a corticosteroid, an analgesic anti-inflammatory agent, a hypnotic sedative, a tranquilizer, an antihypertensive agent, an antihypertensive diuretic, an antibiotic, a general anesthetic, an antibacterial agent, an antifungal agent, a vitamin agent, a coronary vasodilator, an antihistamine, an antitussive, a sex hormone, an antidepressant, a cerebral circulation ameliorating agent, an antiemetic agent, an antitumor agent, an enzyme agent, and a biopharmaceutical.
  • examples of a local drug may include a dental antibiotic such as tetracycline hydrochloride, a disinfectant such as cetyl pyridinium chloride, an infective prophylactic and therapeutic agent such as chlorhexidine hydrochloride, an anti-inflammatory agent such as dimethylisopropylazulene, and an adrenocortical hormone such as hydrocortisone acetate.
  • a dental antibiotic such as tetracycline hydrochloride
  • a disinfectant such as cetyl pyridinium chloride
  • an infective prophylactic and therapeutic agent such as chlorhexidine hydrochloride
  • an anti-inflammatory agent such as dimethylisopropylazulene
  • an adrenocortical hormone such as hydrocortisone acetate.
  • the “drug that volatilizes at room temperature” refers to a drug that volatilizes at from 1° C. to 30° C.
  • the drug susceptible to oxidation, volatilization, and adsorption for example, lidocaine of a local anesthetic and rivastigmine to be used as a therapeutic agent for Alzheimer type dementia (antidementia drug) are used as the target drug.
  • lidocaine to be used in the present invention lidocaine or a pharmaceutically acceptable salt thereof (lidocaine hydrochloride or the like) can be used. These may be contained singly or as a mixture, but it is preferable that lidocaine is singly contained in order to be contained in a drug-containing layer or a drug-containing pressure sensitive adhesive layer to be described later in a dissolved state.
  • the drug-containing layer is an arbitrary layer in a case in which there is a drug-containing pressure sensitive adhesive layer to be described later.
  • the content of the drug in the drug-containing layer is not particularly limited, but it is, for example, from 20 mass % to 95 mass %, preferably from 30 mass % to 90 mass %, and more preferably from 35 mass % to 90 mass % based on the total mass of the drug-containing layer.
  • the blended amount of the drug based on the total mass of the drug-containing layer and the pressure sensitive adhesive layer to be described later is, for example, from 10 mass % to 40 mass %, preferably from 10 mass % to 35 mass %, and more preferably from 10 mass % to 25 mass % in a case in which the drug is rivastigmine.
  • the amount of the drug blended is from 0.1 mass % to 50 mass %, for example, from 1.0 mass % to 10 mass %, and particularly preferably from 2.0 mass % to 8.0 mass % in a case in which the drug is lidocaine.
  • the (meth)acrylic acid alkyl ester resin contained in the drug-containing layer plays a role as a thickening agent, and examples thereof may include a (meth)acrylic acid alkyl ester copolymer and an acrylic pressure sensitive adhesive containing a (meth)acrylic acid ester.
  • EUDRAGIT EPO is particularly preferable from the viewpoint of miscibility with the drug and adhesive property to the support.
  • the content of the (meth)acrylic acid alkyl ester resin in the drug-containing layer is not particularly limited, but it is, for example, from 5 mass % to 25 mass %, preferably from 5 mass % to 20 mass %, and more preferably from 5 mass % to 15 mass % based on the total mass of the drug-containing layer in the case of a (meth)acrylic acid alkyl ester copolymer.
  • the content is, for example, from 20 mass % to 90 mass %, preferably from 30 mass % to 85 mass %, and more preferably from 40 mass % to 80 mass % based on the total mass of the drug-containing layer in the case of an acrylic pressure sensitive adhesive containing a (meth)acrylic acid ester.
  • the drug-containing layer may further contain, other additives such as a softening agent (plasticizer) and an inorganic filler if desired.
  • a softening agent plasticizer
  • an inorganic filler if desired.
  • the tackifier may include a terpene-based tackifier, a terpene phenol-based tackifier, a cumarone indene-based tackifier, a styrene-based tackifier, a rosin-based tackifier, a xylene-based tackifier, a phenol-based tackifier, and a petroleum-based tackifier.
  • the absorption promoter may include terpene oil such as d-limonene, fatty acid esters such as glycerin monolaurate, glycerin monooleate, and diethyl sebacate, and fatty acids such as azone, prothiodecane, oleic acid, lauric acid, and myristic acid or derivatives thereof.
  • terpene oil such as d-limonene
  • fatty acid esters such as glycerin monolaurate, glycerin monooleate, and diethyl sebacate
  • fatty acids such as azone, prothiodecane, oleic acid, lauric acid, and myristic acid or derivatives thereof.
  • the skin permeability of the drug to be blended is improved.
  • a low-polarity resin By further blending a low-polarity resin, the skin permeability of the drug is controlled and the medicinal ingredient can be sustained.
  • a highly polar resin and a low-polarity resin in the pressure sensitive adhesive layer in appropriate amounts, it is possible to continuously administer the medicinal ingredient for a desired period of time, to decrease the residual amount of the medicinal ingredient in the pressure sensitive adhesive layer after being attached, and to realize efficient drug administration.
  • transdermal absorption promoter there are an aliphatic alcohol, a fatty acid, a fatty acid ester, an alcohol amine, a polyhydric alcohol alkyl ether, a polyoxyethylene alkyl ether, glyceride (namely, fatty acid ester of glycerin), a polyhydric alcohol medium chain fatty acid ester, a lactic acid alkyl ester, a dibasic acid alkyl ester, an acylated amino acid, and a pyrrolidone.
  • these transdermal absorption promoters are used singly or in combination of two or more kinds thereof.
  • a drug-containing layer by a so-called “ointment coating method” in which the operation is conducted by avoiding heating as much as possible in the mixing and drying steps instead of a calendering method or hot melt method which includes a heating and kneading (stirring) step and is adopted for the fabrication of a usual patch or a dissolution coating method including a heating and drying step after coating.
  • the “ointment coating method” refers to a method of forming a layer at a low temperature, for example, under a temperature condition of 1° C.
  • the patch was taken out from the packaging bag of the patch product, the release paper was peeled off from the patch, the patch was then immersed in a sealable glass container containing an internal standard solution and tetrahydrofuran for HPLC to dissolve the pressure sensitive adhesive, and a mixed solution of acetonitrile for pharmaceutical/sodium dihydrogen phosphate buffer (pH: 3) was then added to the container to prepare a sample solution (patch).
  • a sealable glass container containing an internal standard solution and tetrahydrofuran for HPLC to dissolve the pressure sensitive adhesive, and a mixed solution of acetonitrile for pharmaceutical/sodium dihydrogen phosphate buffer (pH: 3) was then added to the container to prepare a sample solution (patch).
  • the residual amount of drug (%) was calculated based on the following formula, and the residual amount of drug in the patch was calculated from this value as an average value of 3 times of measurement.
  • the adsorbed amount of drug (%) was calculated based on the following formula, and the average value of 3 times of measurement was calculated from this value and evaluated as follows.
  • Judgment x amount of drug (lidocaine) adsorbed to packaging bag is 1% or more
  • lidocaine By the hot melt method described in the [Method of Manufacturing Patch], lidocaine, SIS 5002 [styrene content: 22 mass %, diblock rate: 15 mass %, manufactured by JSR Corporation] as SIS, PINECRYSTAL KE-311 [hydrogenated rosin glycerin ester, manufactured by Arakawa Chemical Industries, Ltd.] as a highly polar resin, YS Resin PX1150N [terpene resin, manufactured by YASUHARA CHEMICAL CO., LTD.] as a low-polarity resin, and HICALL (registered trademark) M-352 [liquid paraffin, manufactured by Kaneda Corporation] as a softening agent were heated and stirred at the respective blending proportions (the numerical value (mass %) was a numerical value when the total mass of the pressure sensitive adhesive layer was taken as 100 mass %, the same applies hereinafter) of 3.0 mass %, 32.0 mass %, 17.5 mass %, 10.0 mass
  • the heating and stirring were conducted as follows.
  • the above-described materials other than the drug were mixed in a Henschel mixer in a nitrogen atmosphere at a temperature of 170° C. and the number of revolutions of 600 rpm, after the mixture reached a uniform state, the temperature thereof was set at 140° C., and the mixture was stirred for 15 minutes at the number of revolutions of 200 rpm.
  • a pressure sensitive adhesive layer was formed by spreading the pressure sensitive adhesive composition on a silicone-treated polyester film (thickness: 75 ⁇ m) to have a thickness of 200 g/m 2 .
  • a polyester knitted fabric (circular knit, weight per unit area: about 100 g/m 2 , thickness: about 500 ⁇ m) as a support was laminated on this pressure sensitive adhesive layer, and the resultant laminate was cut, thereby fabricating a patch.
  • Example 1 the mass ratio of highly polar resin/low-polarity resin (a numerical value when the total mass of the highly polar resin and the low-polarity resin was taken as 100 mass %) of Example 1 was 82.5/17.5.
  • Laminate configuration COC film/adhesive/aluminum film (AL)/adhesive/polyester film (PET)
  • Polyester film polyethylene terephthalate film, thickness: 12 ⁇ m
  • Aluminum film aluminum foil, thickness: 7 ⁇ m
  • Adhesive polyurethane for adhesive
  • a patch product was fabricated by the same method as in Example 1 except that the innermost layer inside the packaging bag was changed to a polyethylene film (thickness: 30 ⁇ m).
  • Example 1 100 100 99 drug in patch (%) Comparative 100 97 96 96 [stored at 60° C.]
  • the drug (rivastigmine) stability of the patch product of the present invention was evaluated based on the amount of rivastigmine adsorbed to the packaging bag after the lapse of a predetermined period of time.
  • the adsorbed amount of drug (%) was calculated based on the following formula, and the average value of 3 times of measurement was calculated from this value and evaluated as follows.
  • the oxygen concentration was 10 vol % when the oxygen concentration inside the packaging bag was measured by using an oximeter.
  • a patch product was fabricate by the same method as in Example 2 except that the innermost layer of the packaging bag was changed to a polyester film (PET, thickness: 12 ⁇ m).
  • PET polyester film
  • Example 2 From the results in Table 3, it can be seen that a result that the temporal stability of rivastigmine is significantly excellent as the adsorption of drug to the packaging bag is minor (the adsorbed amount of drug is less than 1%) even after the lapse of 14 days under a severe condition of 60° C. has been obtained in Example 2 in which a rivastigmine-containing patch is enclosed in a packaging bag composed of a laminate having a COC film layer as the innermost layer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Botany (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Laminated Bodies (AREA)
  • Medicinal Preparation (AREA)
US15/538,179 2014-12-26 2015-11-18 Packaging body for patch and method of packing patch Abandoned US20170348246A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2014265955 2014-12-26
JP2014-265955 2014-12-26
JP2015069797 2015-03-30
JP2015-069797 2015-03-30
PCT/JP2015/082476 WO2016103999A1 (ja) 2014-12-26 2015-11-18 貼付剤のための包装体および包装方法

Publications (1)

Publication Number Publication Date
US20170348246A1 true US20170348246A1 (en) 2017-12-07

Family

ID=56150032

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/538,179 Abandoned US20170348246A1 (en) 2014-12-26 2015-11-18 Packaging body for patch and method of packing patch

Country Status (6)

Country Link
US (1) US20170348246A1 (ja)
EP (1) EP3238689A4 (ja)
JP (1) JPWO2016103999A1 (ja)
KR (1) KR20170100499A (ja)
CN (1) CN106999343A (ja)
WO (1) WO2016103999A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190209485A1 (en) * 2016-09-16 2019-07-11 Nichiban Co., Ltd. Adhesive skin patch
US20210251916A1 (en) * 2018-06-19 2021-08-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing rivastigmine
US11166921B2 (en) 2018-01-24 2021-11-09 Hisamitsu Pharmaceutical Co., Inc. Patch
US11412766B2 (en) * 2018-06-22 2022-08-16 Desiccare, Inc. Humidity control system
US11833123B2 (en) 2018-09-21 2023-12-05 Kobayashi Pharmaceutical Co., Ltd. Pharmaceutical composition
US11872320B2 (en) 2021-02-25 2024-01-16 Hisamitsu Pharmaceutical Co., Inc. Method for treating osteoarthritis
US12122139B2 (en) 2015-12-29 2024-10-22 Adapa Flexibles Denmark Slagelse A/S Method for providing an extreme chemical resistant film, a film and laminate obtainable therefrom

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019017266A1 (ja) * 2017-07-19 2019-01-24 帝國製薬株式会社 リバスチグミン含有経皮吸収型製剤
JP6976794B2 (ja) * 2017-09-28 2021-12-08 東洋アルミニウム株式会社 包装材及びこれを用いた包装袋
JP2020045106A (ja) * 2018-09-14 2020-03-26 藤森工業株式会社 チャック袋

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01151524A (ja) * 1988-11-10 1989-06-14 Yamanouchi Pharmaceut Co Ltd 左突膏貼付剤及びその製造法
JP3243564B2 (ja) * 1990-08-20 2002-01-07 リードケミカル株式会社 外用貼付剤
JP3227709B2 (ja) * 1991-03-04 2001-11-12 日本ゼオン株式会社 医療用または食品包装用容器
JPH0881363A (ja) * 1994-09-16 1996-03-26 Sekisui Chem Co Ltd 医療用貼付剤包装袋
JP3807178B2 (ja) * 1999-12-17 2006-08-09 凸版印刷株式会社 クリーン性を有する透明防湿包装体
WO2005072716A1 (ja) * 2004-01-30 2005-08-11 Hisamitsu Pharmaceutical Co., Inc. 貼付剤入り包装袋
JP2006044793A (ja) * 2004-07-01 2006-02-16 Nitto Denko Corp 貼付材包装体
JP2006169160A (ja) * 2004-12-15 2006-06-29 Yuutoku Yakuhin Kogyo Kk 外用貼付剤およびその製造方法
WO2008044336A1 (fr) * 2006-10-11 2008-04-17 Hisamitsu Pharmaceutical Co., Inc. Préparation adhésive contenant un cristal
JP2008127042A (ja) * 2006-11-20 2008-06-05 Dainippon Printing Co Ltd 貼付薬用包装袋
JP2011136734A (ja) * 2009-12-28 2011-07-14 Kose Corp 含油液状製剤用包装袋およびこれに含油液状製剤を収納したラミネート包装型製品
JP2012051875A (ja) * 2010-08-03 2012-03-15 Hisamitsu Pharmaceut Co Inc 経皮・経粘膜吸収製剤の保存方法及び経皮・経粘膜吸収製剤包装体
JP5930577B2 (ja) * 2010-10-20 2016-06-08 大日本印刷株式会社 包装袋及び包装容器
JP5678571B2 (ja) * 2010-10-20 2015-03-04 大日本印刷株式会社 包装材用積層体
SG11201400167VA (en) * 2011-08-25 2014-06-27 Nipro Patch Co Ltd Hydrous adhesive skin patch
WO2013047410A1 (ja) * 2011-09-28 2013-04-04 ニチバン株式会社 持続型アルツハイマー病治療用貼付剤及びその製造方法
JP5787157B2 (ja) * 2011-09-30 2015-09-30 Dic株式会社 易引裂き性多層フィルム、その製造方法及び該フィルムを用いた包装材
EP2821070B1 (en) * 2012-02-28 2018-02-21 Nichiban Co. Ltd. Adhesive skin patch
JP6074920B2 (ja) * 2012-05-30 2017-02-08 大日本印刷株式会社 包装材料
WO2014034939A1 (ja) * 2012-09-03 2014-03-06 ニプロパッチ株式会社 貼付剤

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122139B2 (en) 2015-12-29 2024-10-22 Adapa Flexibles Denmark Slagelse A/S Method for providing an extreme chemical resistant film, a film and laminate obtainable therefrom
US20190209485A1 (en) * 2016-09-16 2019-07-11 Nichiban Co., Ltd. Adhesive skin patch
US10828264B2 (en) * 2016-09-16 2020-11-10 Nichiban Co., Ltd. Adhesive skin patch
US11166921B2 (en) 2018-01-24 2021-11-09 Hisamitsu Pharmaceutical Co., Inc. Patch
US20210251916A1 (en) * 2018-06-19 2021-08-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing rivastigmine
US11412766B2 (en) * 2018-06-22 2022-08-16 Desiccare, Inc. Humidity control system
US11833123B2 (en) 2018-09-21 2023-12-05 Kobayashi Pharmaceutical Co., Ltd. Pharmaceutical composition
US11872320B2 (en) 2021-02-25 2024-01-16 Hisamitsu Pharmaceutical Co., Inc. Method for treating osteoarthritis

Also Published As

Publication number Publication date
EP3238689A4 (en) 2018-08-08
WO2016103999A1 (ja) 2016-06-30
EP3238689A1 (en) 2017-11-01
KR20170100499A (ko) 2017-09-04
JPWO2016103999A1 (ja) 2017-10-05
CN106999343A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
US20170348246A1 (en) Packaging body for patch and method of packing patch
KR101843966B1 (ko) 첩부제
EP2431034B1 (en) Adhesive patch-containing package bag and method for storing adhesive patch
US20190060248A1 (en) Percutaneous absorption preparation
US20070128262A1 (en) Package containing adhesive patch and method of inhibiting drug migration
US10308408B2 (en) Packaging for adhesive patch containing rivastigmine
EP2377515A1 (en) Patch preparation and production method thereof
KR20180089394A (ko) 첩부제의 포장 구조
WO2017094337A1 (ja) 貼付剤
US10828264B2 (en) Adhesive skin patch
WO2017170933A1 (ja) 貼付剤製品
JP2007022939A (ja) 外用貼付剤
JP2024109240A (ja) Ｓ－フルルビプロフェン含有貼付剤包装製品並びにｓ－フルルビプロフェン及びｌ－メントールの安定化方法
JP6290521B1 (ja) 貼付剤
EP4299130A1 (en) Packaged product of diclofenac-containing adhesive patch and method for stabilizing diclofenac sodium
US20200405653A1 (en) Methylphenidate-containing transdermal patch
TW202126488A (zh) 包裝材
NZ628326B2 (en) Transdermal Patch

Legal Events

Date Code Title Description
AS Assignment

Owner name: NICHIBAN CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TOHARA, YUKIKO;MATSUO, KYOHEI;OHBA, AYAKA;AND OTHERS;SIGNING DATES FROM 20170607 TO 20170614;REEL/FRAME:043028/0871

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION